



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: CAMPBELL2A

In re Patent of:) Conf. No.: 7975
)
Robert K. CAMPBELL et al)
)
Patent No.: 6,663,867 **B B2**) Washington, D.C.
)
Issued: December 16, 2003) April 8, 2005
)
For: HYBRID HETERODIMERIC)
PROTEIN HORMONE COMPRISING) ATTN: Certificate of
A TNF BINDING PROTEIN AND) Correction Division
A GLYCOPROTEIN HORMONE)
SUBUNIT AND METHOD OF)
USING SAME)

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322
AND §1.323

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Randolph Building, Mail Stop
401 Dulany Street
Alexandria, VA 22314

Certificate
APR 12 2005
of Correction

Sir:

In checking over the printed copy of the above-identified patent, we have found the following errors, some of which are the fault of the Patent and Trademark Office and some of which are not the fault of the Patent and Trademark Office.

It is respectfully requested that the errors of the Patent and Trademark Office be corrected in accordance with 37 CFR §1.322(a). The errors to be corrected are listed below.

On the patent face, section (57), the Abstract, line 8, "hoscells" should read "host cells". See the Abstract of the Disclosure in the application as filed, page 47, line 9.

04/11/2005 MBIZUNES 00000097 6663867

01 FC:1811

100.00 OP

APR 13 2005

COFC
\$
#6
L.M.N.

Column 7, line 19, "TBP(20-161)-hCG α " should read "TBP(20-161)-hCG β ". See the specification as filed at page 12, line 9.

Column 7, line 22, "TBP(20-190)-hCG α " should read "TBP(20-190)-hCG β ". See the specification as filed at page 12, line 12.

It is respectfully requested that the errors that are not the fault of the Patent and Trademark Office be corrected in accordance with 37 CFR §1.323. The errors to be corrected are listed below.

Column 3, line 13, it is requested that "heterodimer" be changed to read "a heterodimer".

Column 5, line 24, it is requested that "yeasts" be changed to read "yeast".

Column 8, line 10, it is requested that "Wallach" be changed to read "Nophar". Wallach is identified as the author of reference 40. In the specification as filed on page 31, line 1, the author of reference 40 is correctly identified as "Nophar".

Patent claim 2, line 3 (column 42, line 16) residues "20-~~262~~" should read "20-161". Nowhere else in the specification are these amino acid residues of TBP1 set forth as "20-262". In support of the residues being "20-161", see:

- specification as filed at page 12, lines 8-9, and column 7, lines 18-19, of the patent, "TBP(20-161)-hCG α " and "TBP(20-161)-hCG β " (as corrected above);

- specification as filed at page 12, lines 26-27, and column 7, lines 37-38, of the patent, "TBP-hCG(20-161)";
- specification as filed at page 14, line 1, and column 8, line 32, of the patent, "TBP1(20-161)-hCG";
- specification as filed at page 14, line 7, and column 8, line 39, of the patent, "TBP1(20-161)-hCG)";
- specification as filed at page 14, lines 8-9, and column 8, lines 40-41, of the patent, "TBP1(20-161)-hCG α and TBP1(20-161)-hCG β ";
- specification as filed at page 14, line 11, and column 8, lines 43-44, of the patent, "TBP1(20-161)-hCG α ";
- specification as filed at page 14, line 27, and column 8, line 66, of the patent, "TBP1(20-161)-hCG β ";
- specification as filed at page 15, line 28, and column 9, line 41, of the patent, "TBP1(20-161)-hCG α ";
- specification as filed at page 16, line 22, and column 10, line 23, of the patent, "TBP1(20-161)-hCG α ";
- specification as filed at page 16, line 26, and column 10, line 28, of the patent, "TBP1(20-161)-hCG β ";

- specification as filed at page 16, lines 27-28, and column 10, lines 29-30, of the patent, "TBP(20-161)-hCG α ";
- specification as filed at page 16, line 35, and column 10, line 38, of the patent, "TBP(20-161)-hCG";
- specification as filed at page 21, line 35, and column 13, line 34, of the patent, "TBP(20-161)-hCG";
- specification as filed at page 23, line 8, and column 14, line 21, of the patent, "TBP(20-161)-hCG";
- specification as filed at page 23, line 12, and column 14, line 27, of the patent, "TBP(20-161)-hCG";
- specification as filed at page 26, Table 1, lines 5, 6 and 7, and column 15, Table 1, lines 62, 63 and 64, of the patent, "TBP(20-161)-hCG α ", "TBP(20-161)-hCG β " and "TBP(20-161)-hCG", respectively;
- specification as filed at page 27, Table 4, line 5, and column 16, Table 4, line 38, of the patent, "TBP(20-161)-hCG"; and
- specification as filed at page 28, Table 5, line 7, and column 16, Table 5, line 53, of the patent, "TBP(20-161)-hCG".

It, therefore, is clear that the recitation of residues "20-262" in patent claim 2 is a clear error and should read "20-161".

Patent claim 2, line 4 (column 42, line 17) residues "20-290" should read "20-190". Nowhere else in the specification are these amino acid residues of TBP1 set forth as "20-290". In support of the residues being "20-190", see:

- specification as filed at page 12, lines 11 and 12, and column 7, lines 21 and 22, of the patent, "TBP(20-190)-hCG α " and "TBP(20-190-hCG β " (as corrected above);
- specification as filed at page 12, line 20, and column 14, line 29, of the patent, "TBP(20-190)-hCG";
- specification as filed at page 12, line 23, and column 14, line 33, of the patent, "TBP(20-190)-hCG";
- specification as filed at page 16, line 33, and column 10, line 36, of the patent, "TBP(20-190)-hCG";
- specification as filed at page 18, line 34, and column 11, line 7, of the patent, "pSVLTBP(20-190)-hCG α ";
- specification as filed at page 12, line 11, and column 11, line 25, of the patent, "pSVLTBP(20-190)-hCG β ";

- specification as filed at page 23, line 10, and column 14, line 23, of the patent, "TBP(20-190)-hCG";
- specification as filed at page 23, line 13, and column 14, line 28, of the patent, "TBP(20-190)-hCG";
- specification as filed at page 26, Table 2, lines 5, 6 and 7, and column 16, Table 2, lines 9, 10 and 11, of the patent, "TBP(20-190)-hCG α ", "TBP(20-190)-hCG β " and "TBP(20-190)-hCG", respectively;
- specification as filed at page 26, Table 3, lines 5, 6 and 7, and column 16, Table 3, lines 23, 24 and 25, of the patent, "TBP(20-190)-hCG α ", "TBP(20-190)-hCG β " and "TBP(20-190)-hCG", respectively;
- specification as filed at page 27, Table 4, lines 7 and 8, and column 16, Table 4, line 39 and 40, of the patent, "TBP(20-161)-hCG" and "TBP(20-161)-hCG", respectively; and
- specification as filed at page 28, Table 5, lines 8, and column 16, Table 5, line 54, of the patent, "TBP(20-161)-hCG".

It, therefore, is clear that the recitation of residues "20-290" in patent claim 2 is a clear error and should read "20-190".

When the changes are considered, it will be clear that the errors not the fault of the Patent and Trademark Office are of a typographical or clerical error in nature

In re of U.S. Patent 6,663,867

and/or of minor character, which occurred in good faith. Correction thereof does not involve such changes in the patent as would constitute "new matter" or would require re-examination.

Attached please find PTO Form 2038 authorizing payment in the amount of \$100.00 to cover the appropriate fee for corrections under 37 CFR §1.323. If insufficient fees are specifically authorized, please charge same to Deposit Account No. 02-4035.


We are also attaching one copy of the Certificate of Correction form.

Granting of this request is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Allen C. Yun
Registration No. 37,971

ACY:rd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\S\Ser1\campbell12c\pto\CertCor322&323.doc

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,663,867 B2
DATED : December 16, 2003
INVENTOR(S) : Robert K. Campbell, Bradford A. Jameson and Scott C. Chappel

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.

Item [57], **ABSTRACT**,

Line 8, delete "hoscells" and insert therefor -- host cells --

Column 3.

Line 13, before "heterodimer" insert -- a --

Column 5.

Line 24, delete "yeasts" and insert therefor -- yeast --

Column 7.

Line 19, delete "TBP (20-161) -hCG α " and insert therefor -- TBP (20-161) -hCG β --

Line 22, delete "TBP (20-190) -hCG α " and insert therefor -- TBP (20-161) -hCG β --

Column 8.

Line 10, delete "Wallach" and insert therefor -- Nophar --

Line 16, delete "20-262" and insert therefor -- 20-161 --

Line 17, delete "20-290" and insert therefor -- 20-190 --

APPROVED

OCT 25 2005

FOR THE DIRECTOR OF USPTO

Signed and Sealed this

Twenty-first Day of June, 2005

JON W. DUDAS
Director of the United States Patent and Trademark Office

#7
SUPERS EDC
CJCE
Contractor placed last two errors under column 8, should be placed under column 4a

18/25/2005
9.9.
per conversation with attorney 10/20/2005
10/19/05
JW

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,663,867 B2
 DATED : December 16, 2003
 INVENTOR(S) : Robert K. Campbell; Bradford A. Jameson; and Scott C. Chappel

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

- 1) Patent Face, Section (57), Abstract, line 8, delete "hoscells" and insert therefor --host cells--
- 2) Column 3, line 13, before "heterodimer" insert --a--
- 3) Column 5, line 24, delete "yeasts" and insert therefor --yeast--
- 4) Column 7, line 19, delete "TBP(20-161)-hCG α " and insert therefor --TBP(20-161)-hCG β --
- 5) Column 7, line 22, delete "TBP(20-190)-hCG α " and insert therefor --TBP(20-161)-hCG β --
- 6) Column 8, line 10, delete "Wallach" and insert therefor --Nophar--
- 7) Column 42, line 16 (claim 2, line 3), delete "20-262" and insert therefor --20-161--
- 7) Column 42, line 17 (claim 2, line 3), delete "20-290" and insert therefor --20-190--

MAILING ADDRESS OF SENDER:

BROWDY AND NEIMARK
 624 Ninth Street, NW
 Suite 300
 Washington, DC 20001-5303

PATENT NO. 6,663,867 B2

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

APR 13 2005

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,663,867 B2
DATED : December 16, 2003
INVENTOR(S) : Robert K. Campbell, Bradford A. Jameson and Scott C. Chappel

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.

Item [57], **ABSTRACT**,

Line 8, delete "hoscells" and insert therefor -- host cells --

Column 3.

Line 13, before "heterodimer" insert -- a --

Column 5.

Line 24, delete "yeasts" and insert therefor -- yeast --

Column 7.

Line 19, delete "TBP (20-161) -hCG α " and insert therefor -- TBP (20-161) -hCG β --

Line 22, delete "TBP (20-190) -hCG α " and insert therefor -- TBP (20-161) -hCG β --

Column 8.

Line 10, delete "Wallach" and insert therefor -- Nophar --

Line 16, delete "20-262" and insert therefor -- 20-161 --

Line 17, delete "20-290" and insert therefor -- 20-190 --


Column 42

*Last two errors
should be placed
under Column 42

This certificate supersedes certificate of correction
Issued June 21, 2005.

Signed and Sealed this

Twenty-first Day of June, 2005



By William D. B. A.
Director of the United States Patent and Trademark Office

Note

INSERT

Note

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,663,867 B2
DATED : December 16, 2003
INVENTOR(S) : Robert K. Campbell, Bradford A. Jameson and Scott C. Chappel

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page,

Item [57], **ABSTRACT,**

Line 8, delete "hoscells" and insert therefor -- host cells --

Column 3,

Line 13, before "heterodimer" insert -- a --

Column 5,

Line 24, delete "yeasts" and insert therefor -- yeast --

Column 7,

Line 19, delete "TBP (20-161) -hCG α " and insert therefor -- TBP (20-161) -hCG β --

Line 22, delete "TBP (20-190) -hCG α " and insert therefor -- TBP (20-161) -hCG β --

Column 8,

Line 10, delete "Wallach" and insert therefor -- Nophar --

Line 16, delete "20-262" and insert therefor -- 20-161 --

Line 17, delete "20-290" and insert therefor -- 20-190 --

Column 42

Signed and Sealed this

Twenty-first Day of June, 2005



JON W. DUDAS
Director of the United States Patent and Trademark Office

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,663,867 B2
DATED : December 16, 2003
INVENTOR(S) : Robert K. Campbell, Bradford A. Jameson and Scott C. Chappel

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page.

Item [57], **ABSTRACT**,

Line 8, delete "hoscells" and insert therefor -- host cells --.

Column 3.

Line 13, before "heterodimer" insert -- a --.

Column 5.

Line 24, delete "yeasts" and insert therefor -- yeast --.

Column 7.

Line 19, delete "TBP (20-161) -hCG α " and insert therefor -- TBP (20-161) -hCG β --.

Line 22, delete "TBP (20-190) -hCG α " and insert therefor -- TBP (20-161) -hCG β --.

Column 8.

Line 10, delete "Wallach" and insert therefor -- Nophar --.

Column 42.


Line 16, delete "20-262" and insert therefor -- 20-161 --.

Line 17, delete "20-290" and insert therefor -- 20-190 --.

This certificate supersedes Certificate of Correction issued June 21, 2005.

Signed and Sealed this

Sixth Day of December, 2005



JON W. DUDAS
Director of the United States Patent and Trademark Office